Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Overall research band Weak

Quality Mixed

Valuation Weak

Balance sheet Very weak

Market confirmation Above average

One-minute company read

What this report can tell you now

What the company does

Amneal Pharmaceuticals, Inc. is a diversified pharmaceutical company headquartered in Bridgewater, New Jersey, operating through three divisions: Generics, Specialty, and AvKARE. The company develops, manufactures, markets, and distributes a broad range of generic and specialty pharmaceutical products in various forms, including oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalants, and transdermal patches. Its Specialty division focuses on branded pharmaceuticals for neurological, endocrine, and parasitic conditions, with products such as Emverm, Rytary, and Unithroid. The AvKARE segment supplies pharmaceuticals and medical supplies primarily to U.S. government agencies, including the Department of Defense and Department of Veterans Affairs, and also distributes medications and supplements to retail and institutional customers. Amneal's products are sold through wholesalers, distributors, hospitals, pharmacy chains, and independent drugstores, with operations spanning the United States, India, Ireland, and other international markets.

The current research profile is Balanced Opportunity, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC16.4%Model input; read with the evidence status and period context.

Operating margin14.0%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years9.6%Model input; read with the evidence status and period context.

FCF margin8.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.